Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus SPARINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus SPARINE.
CHLORPROMAZINE HYDROCHLORIDE vs SPARINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
Phenothiazine antipsychotic; blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors; also blocks alpha-adrenergic receptors, and has anticholinergic and antihistaminergic effects.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
Promazine hydrochloride: 25-50 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 300 mg/day. Alternatively, oral: 25-200 mg every 4-6 hours; maximum 1000 mg/day. Route and frequency depend on indication and patient response.
None Documented
None Documented
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Terminal elimination half-life: 10-20 hours; clinical context: allows once or twice daily dosing; extended in elderly and hepatic impairment
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Primarily renal (70-80% as metabolites, less than 1% unchanged); biliary/fecal (15-30%)
Category C
Category C
Antipsychotic
Antipsychotic